Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Avalon Pharmaceuticals has reported positive preliminary results showing that AVN944 is well tolerated in refractory adult acute myelogenous leukemia patients, with drug exposure increasing with higher dose levels.
Subscribe to our email newsletter
The company said that AVN944 biomarkers show a dose-dependent increase in activity including, binding to the target enzyme IMPDH, depletion of GTP pools in blast cells and gene expression markers correlating to cell cycle blocks, GTP level and apoptosis, illustrating that biomarkers can be used to monitor exposure in patients as dose levels increase.
Utilizing the AvalonRx platform, a predictive algorithm was developed and the preliminary data discriminates AVN944’s effect on patients with regard to disease stabilization or progression. The company said that this biomarker-based patient stratification strategy could provide a valuable tool for enrichment of patients more likely to benefit from AVN944 therapy in future studies.